Elsevier

The Lancet

Volume 346, Issues 8991–8992, 30 December 1995, Pages 1666-1669
The Lancet

COMMENTARY
Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation

https://doi.org/10.1016/S0140-6736(95)92840-5Get rights and content

Abstract

Up to a third of patients have early rebleeding from oesophageal varices after endoscopic variceal ligation. Octreotide infusion is effective for control of variceal bleeding. We investigated the efficacy of octreotide infusion as an adjunct to endoscopic variceal ligation to prevent early rebleeding from varices. 100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 μg intravenous bolus injection followed by intravenous infusion at 50 μg per h for 5 days) plus endoscopic variceal ligation. Three patients in each group were excluded. Bleeding was controlled in 44 of 47 patients who received variceal ligation alone and in 45 of 47 who received combined treatment (p=1·0). Recurrent bleeding was documented in 18 (38% [24-52]) patients who received variceal ligation alone and in four (9% [3-21] who received combined treatment (p=0·0007). The relative risk of rebleeding was lower (0·22 [0·08-0·60]) in the combined therapy group. Ten patients in the variceal ligation group and one in the combined therapy group required balloon tamponade for massive haematesis and haemodynamic instability (p=0·0039). The in-hospital and 30-day mortality rates were higher in the variceal ligation group than in the combined therapy group (19 vs 9% and 23 vs 11%), but the differences did not reach significance. The relative risks of in-hospital (0·5 [0·04-5·3]) and 30-day (0·45 [0·17-1·2]) mortality were lower in the combined therapy group. Octreotide significantly reduces recurrent bleeding and the need for balloon tamponade in patients with variceal haemorrhage treated by endoscopic variceal ligation.

Cited by (196)

  • Management of liver failure in general intensive care unit

    2020, Anaesthesia Critical Care and Pain Medicine
    Citation Excerpt :

    Splanchnic vasoconstrictor agents such as somatostatin, octreotide and terlipressin exert their vasoactive effects and decrease splanchnic blood flow and portal pressure. In patients with acute variceal bleeding who are undergoing endoscopic sclerotherapy, several studies showed that the early intravenous administration of a vasoactive agent was more effective than placebo in the overall control of haemorrhage [173–175]. In one meta-analysis published in 2012 [176], the use of vasoactive agents was associated with a significantly lower risk of mortality at 7 days (RR 0.74; 95% CI 0.57–0.95; P = 0.02), fewer transfusion requirements and a shorter duration of hospitalisation.

  • Endoscopic management of acute esophageal variceal bleeding

    2017, Techniques in Gastrointestinal Endoscopy
  • Current Pharmacological Management in Upper Gastrointestinal Bleeding

    2023, Proceedings of the Shevchenko Scientific Society. Medical Sciences
View all citing articles on Scopus
View full text